EOLS

Dopo l'orario di chiusura: 12.03

Evolus Inc (EOLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Evolus Inc Stock (EOLS) Company Profile

Healthcare (1164)

(949) 284-4555

520 NEWPORT CENTER DRIVE, NEWPORT BEACH

@evolusaesthetic

Prossima data di guadagno

Ultimi documenti SEC

EOLS's Discussions on Twitter

Confronta EOLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EOLS Evolus Inc	12.03	778.30M	202.09M	-61.69M	-35.64M	-1.08
ZTS Zoetis Inc	164.65	73.07B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	14.87	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.29	45.72B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.37	17.71B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	308.27	14.37B	2.76B	1.11B	898.10M	22.77

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-29	Aggiornamento	Barclays	Equal Weight → Overweight
2022-06-23	Iniziato	Needham	Buy
2022-05-12	Aggiornamento	Barclays	Underweight → Equal Weight
2022-01-20	Aggiornamento	Truist	Hold → Buy
2021-05-06	Aggiornamento	Mizuho	Neutral → Buy
2021-04-08	Reiterato	H.C. Wainwright	Buy
2021-02-24	Downgrade	Truist	Buy → Hold
2020-07-07	Downgrade	Mizuho	Buy → Neutral
2020-02-06	Ripresa	Mizuho	Buy
2019-11-26	Iniziato	SVB Leerink	Outperform
2019-09-05	Ripresa	Mizuho	Buy
2019-06-28	Iniziato	Wells Fargo	Market Perform
2019-06-11	Iniziato	Barclays	Underweight
2019-03-20	Iniziato	SunTrust	Buy
2019-02-14	Iniziato	H.C. Wainwright	Buy
2019-01-29	Iniziato	Stifel	Buy

Mostra tutto

Evolus Inc Borsa (EOLS) Ultime notizie

Evolus Inc Azioni (EOLS) Dati Finanziari

Evolus Inc (EOLS)

Evolus Inc Stock (EOLS) Company Profile

Confronta EOLS con altri titoli

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Evolus Inc Borsa (EOLS) Ultime notizie

Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com Australia

Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com India

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace

Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus

Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - Stock Titan

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 - BioSpace

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Finance

Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener

Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia

Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire

Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa

Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com

Evolus executive Avelar Rui sells $369,867 in stock - Investing.com India

Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India

Evolus chief marketing officer sells $60,124 in common stock - Investing.com

When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com

Evolus Executives Sell Shares to Cover Tax Obligations - TradingView

Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St

Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire

Evolus director Parschauer sells $167,465 in common stock - Investing.com India

Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com South Africa

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India

Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa

Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India

Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool

What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World

(EOLS) Investment Analysis - Stock Traders Daily

Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN

Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World

Evolus, Inc. to Host Earnings Call - ACCESS Newswire

Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World

IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World

Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks

HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World

Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks

Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks

Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com

Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa

H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com

Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize

Assessing Evolus: Insights From 6 Financial Analysts - Benzinga

Evolus price target raised to $25 from $22 at Barclays - TipRanks

Evolus reports Q4 EPS (11c) vs (21c) last year - TipRanks

Evolus Inc Azioni (EOLS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a EOLS